ROCKWELL MEDICAL, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
ROCKWELL MEDICAL, INC. (RMTI) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $2.01 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-21.
Discontinued › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2024-03-21
- ROCKWELL MEDICAL, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-12-31 was $495.00K, a 7.48% decline year-over-year.
- ROCKWELL MEDICAL, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-09-30 was $491.00K, a 7.91% increase year-over-year.
- ROCKWELL MEDICAL, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-06-30 was $507.00K, a 13.93% increase year-over-year.
- ROCKWELL MEDICAL, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-03-31 was $520.00K, a 26.21% increase year-over-year.
- ROCKWELL MEDICAL, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $2.01M, a 0.15% decline from fiscal 2022.
- ROCKWELL MEDICAL, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $2.01M, a 8.99% increase from fiscal 2021.
- ROCKWELL MEDICAL, INC. operating lease, right-of-use asset, amortization expense for fiscal 2021 was $1.85M, a 26.94% increase from fiscal 2020.
- ROCKWELL MEDICAL, INC. operating lease, right-of-use asset, amortization expense for fiscal 2020 was $1.46M, a 21.98% decline from fiscal 2019.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2023-12-31 | $2.01M 10-K · filed 2024-03-21 | |||
| 2022-12-31 | $495.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $986.00K derived: sum of 2 quarters · filed 2024-03-21 | $1.49M derived: sum of 3 quarters · filed 2024-03-21 | $2.01M 10-K · filed 2024-03-21 |
| 2022-09-30 | $491.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $998.00K derived: sum of 2 quarters · filed 2022-11-14 | $1.52M 10-Q · filed 2022-11-14 | $2.05M derived: sum of 4 quarters · filed 2023-03-30 |
| 2022-06-30 | $507.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $1.03M 10-Q · filed 2022-08-15 | $1.56M derived: sum of 3 quarters · filed 2023-03-30 | $2.02M derived: sum of 4 quarters · filed 2023-03-30 |
| 2022-03-31 | $520.00K 10-Q · filed 2022-05-16 | $1.05M derived: sum of 2 quarters · filed 2023-03-30 | $1.51M derived: sum of 3 quarters · filed 2023-03-30 | $1.96M derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-12-31 | $535.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $990.00K derived: sum of 2 quarters · filed 2023-03-30 | $1.44M derived: sum of 3 quarters · filed 2023-03-30 | $1.85M 10-K · filed 2023-03-30 |
| 2021-09-30 | $455.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $900.00K derived: sum of 2 quarters · filed 2022-11-14 | $1.31M 10-Q · filed 2022-11-14 | $1.68M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $445.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $857.00K 10-Q · filed 2022-08-15 | $1.22M derived: sum of 3 quarters · filed 2022-08-15 | $1.56M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $412.00K 10-Q · filed 2022-05-16 | $777.00K derived: sum of 2 quarters · filed 2022-05-16 | $1.12M derived: sum of 3 quarters · filed 2022-05-16 | $1.48M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $365.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-08 | $707.00K derived: sum of 2 quarters · filed 2022-04-08 | $1.06M derived: sum of 3 quarters · filed 2022-04-08 | $1.46M 10-K · filed 2022-04-08 |
| 2020-09-30 | $342.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $699.00K derived: sum of 2 quarters · filed 2021-11-15 | $1.09M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $357.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $748.00K 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $391.00K 10-Q · filed 2021-05-17 | |||
| 2019-12-31 | $1.86M 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B |